Related Experiment Video

Updated: Sep 6, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K

MDMA for the Treatment of Negative Symptoms in Schizophrenia

Mitchell D Arnovitz1, Andrew J Spitzberg1, Ashkhan J Davani1

  • 1Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Queens, NY 11004, USA.

Journal of Clinical Medicine
|June 24, 2022
PubMed

Insights

3,4-Methylenedioxy methamphetamine (MDMA) may offer a novel treatment for schizophrenia

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Schizophrenia's negative symptoms impose a significant economic burden and limit daily functioning.
  • Current treatments for negative symptoms are lacking, with ongoing debate regarding their measurement and classification.
  • 3,4-Methylenedioxy methamphetamine (MDMA) shows therapeutic potential due to its effects on social interaction, empathy, and brain plasticity.

Purpose of the Study:

  • To review the existing literature on negative symptoms of schizophrenia, their treatment challenges, and the therapeutic potential of MDMA.
  • To provide a rationale for investigating MDMA-assisted therapy for negative symptoms.
  • To examine evidence supporting the safety and efficacy of MDMA for treating negative symptoms.

Main Methods:

  • Literature review of studies on schizophrenia negative symptoms, MDMA, and MDMA-assisted therapy.
  • Analysis of evidence regarding MDMA's effects on social cognition, empathy, and neuroplasticity.
  • Synthesis of safety and efficacy data for MDMA in therapeutic contexts.

Main Results:

  • MDMA has demonstrated potential in enhancing social interaction and empathy, which are often impaired in schizophrenia.
  • Evidence suggests MDMA may induce metaplasticity, potentially counteracting negative symptoms.
  • Recent findings support the potential safety and effectiveness of MDMA for treating negative symptoms.

Conclusions:

  • MDMA-assisted therapy presents a promising avenue for addressing the unmet needs in treating schizophrenia's negative symptoms.
  • Further research is warranted to elucidate the mechanisms of action and optimize treatment protocols.
  • Considerations for safety and regulatory pathways are crucial for clinical implementation.
Keywords:
MDMAnegative symptomspsychedelic-assisted therapypsychosisschizophrenia

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.6K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

3.7K

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
326
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
117
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
207
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
444
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260